NCT
INICIO RECIENTES ARCHIVO COVID-19
INICIO RECIENTES ARCHIVO PUBLICAR INSTRUCCIONES
PARA AUTORES COVID-19 ENTRAR / REGISTRARSE HISTORIA NOSOTROS DIRECTORIO CONTACTO
Consideraciones a los resultados de tratamiento en pacientes con tuberculosis resistente a múltiples fármacos (TB MDR). Una revisión de la literatura

Dina Martínez Mendoza, Enrique López Segundo, Alfredo Torres Cruz, Víctor Ruiz Piña, María de los Ángeles Mora Pizano, Miguel Ángel Salazar Lezama





2008, Número 1

2008; 67 (1)






RESUMEN

La tuberculosis multifarmacorresistente (MDR), definida como aquélla en que la cepa es resistente al menos a isoniazida y rifampicina, es el resultado de un mal manejo en el pasado, y un fenómeno creado por el hombre. Existen evidencias y controversias en el tratamiento y curación de los pacientes con TB MDR. Los trabajos revisados en este estudio demuestran tasas de curación que van del 33 al 77%, las definiciones de curación varían entre los trabajos publicados. Aunque la factibilidad y costo-efectividad de tratar pacientes con TB MDR en países de medianos-bajos recursos está bien establecido, el éxito de tratamiento permanece subóptimo, principalmente debido a la duración del mismo y a los efectos adversos.

PALABRAS CLAVE

TB MDR, TAES, respuesta a tratamiento, fracaso, adherencia, estandarizado, individualizado.

REFERENCIAS

  1. Guidelines for the programatic management of drug-resistant tuberculosis. Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.361).

  2. Nettleman MD. Multidrug-Resistant Tuberculosis News from the front. JAMA 2005; 293(22): 2788-2790.

  3. Salazar-Lezama MA. Tratamiento de la tuberculosis farmacorresistente. Gac Méd Méx 2003; 139(5): 487-490.

  4. Burgos M, González LC, Paz EA, Gournis E, Kawamura LM, Schecter G, Hopewell PC, Daley CL. Treatment of multidrug-resistant tuberculosis in San Francisco: An outpatient-based approach. CID 2005: 40 (1 April).

  5. Ollé-Goig JE, Sandy R. Outcomes of individualized treatment for multidrug-resistant tuberculosis before DOTS-Plus. Int J Tuberc Lung Dis 2005; 9(7): 765-770.

  6. Flement-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France a nationwide case-control study. Am J Respir Crit Care Med 1999; 160: 587-593.

  7. Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, et al. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis 2005; 9(5): 507-513.

  8. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.

  9. Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at chest clinic. Int J Tuberc Lung Dis 2001; 5(12): 1129-1136.

  10. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 Patients with Pulmonary Tuberulosis Resistant to Isoniazid and Rifampin. N Engl J Med 1993; 328: 527-532.

  11. Salazar-Lezama MA, Torres-Cruz A, Valdez-Vázquez R, López-Segundo E, Villarreal-Velarde H, Quiñones Falconi F, et al. Resultados de tratamiento de tuberculosis resistente en 91 pacientes del Instituto Nacional de Enfermedades Respiratorias: 2001-2003. Rev Inst Nal Enf Resp Mex 2004; 17(1): 15-21.

  12. Pérez-Guzmán C, Vargas MH, Martínez-Rossier LA, Torres-Cruz A, Villarreal-Velarde H. Result of a 12-month regimen for drug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 6(12): 1-8.

  13. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8(3): 361-368.

  14. Tahao lu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, Özmen I, Kapakli N. The Trealment of Multidrug-resistant Tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.

  15. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh MN, Goble M, Iseman MD. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.

  16. Ward HA, Marciniuk DD, Hoeppner VH, Jones W. Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants. Int J Tuberc Lung Dis 2005; 9(2): 164-169.

  17. Escudero E, Peña JM, Álvarez-Sala R, Vázquez JJ, Ortega A. Multidrug-resistant tuberculosis without HIV infection: success with individualized therapy. Int J Tuberc Lung Dis 2006; 10(4): 409-414.

  18. Park SK, Tim SD, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2(11): 877-884.

  19. Wai YW, Kuen CC, Hung CC, Ming TC, Chiu LC, Chuen WP, Lee J. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. CHEST 2000; 117: 744-751.

  20. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Andreev YG, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006; 10(4): 402-409.

  21. Van DA, Hamid SM, Kumar DA, Bastian I, Portales F. Results of a standardized regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8(5): 560-567.

  22. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1993 prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324.

  23. Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik AE, Ashkin D. Treatment Experience of Multidrug-Resistant Tuberculosis in Florida, 1994-1997. Chest 2001; 120: 343-348.

  24. Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr W, et al. Multidrug-Resistant Tuberculosis in Patients without HIV Infection. N Engl J Med 1995; 333: 907-911.

  25. Holtz TH, Sternberg M, Kammerer S, Laserson K F, Riekstina V, Zarovska E, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: Predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659.

  26. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.

  27. Nathason E, Lambregts C, Rich M, Gupta R, Bayona J, Blönda K, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infec Dis 2006; 12: 1389-1397.

  28. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9(6): 640-645.

  29. Kwonjune JS, Irina EG, Gennadiy GP, Vera TG, Vera EP, Olga BS, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. CID 2004; 39: 1321-1328.

  30. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005; 25: 928-936.

  31. DeRiemer K, García-García L, Bobadilla-del-Valle M, Palacios-Martínez M, Martínez-Gamboa A, Small PM et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005; 365: 1239-1245.

  32. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 10(8): 829-837

  33. Mitnick CD, Castro KG, Harrington M, Sacks Burman W. (2007). Randomized trials to optimize treatment of multidrug-resistant tuberculosis. Plos Med 4(11);e292.doi:10.1371/journal.pmed.0040292.


2008, Número 1

2008; 67 (1)